A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Phase 3Recruiting
- Lead sponsor
- Amgen (Industry)
- Enrollment
- 750 (estimated)
- Start date
- 28 Nov 2025
- Primary completion
- 7 Jan 2030 (estimated)
- Study completion
- 30 Aug 2032
- Last update posted
- 20 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Xaluritamig Drug
- Abiraterone acetate Drug
- Docetaxel Drug
- Cabazitaxel Drug
Conditions and primary outcome
- Metastatic Castration-resistant Prostate Cancer
Primary outcome
OS (Up to approximately 51 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07213674.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07213674 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.